LEO Pharma to Present 17 Scientific Abstracts at AAD 2026 Highlighting Real--World Evidence, Long--Term Outcomes and Patient Experience Across Multiple Dermatological Conditions

LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 17 scientific posters at the 2026 American Academy of Dermatology (AAD) Annual Meeting (March 27-31, Denver, ...

Stress-activated pathway reveals how nervous system contributes to eczema flare-ups

The mystery of how stress exacerbates atopic dermatitis, more commonly known as eczema, may be closer to being understood. A new study published in the journal Science has identified a specific nerve ...
Everyday Health on MSN

Why primary biliary cholangitis causes itching — and how to find relief

Learn why primary biliary cholangitis (PBC) causes intense itching, and explore treatment options, management tips, and skin-care strategies for relief.
Managed Healthcare Executive

FDA approves treatment for debilitating itch in rare liver disease

Lynavoy is used to treat cholestatic pruritus, an extreme itch that affects almost 90% of patients with primary biliary cholangitis.
Morning Overview on MSN

Study maps nerve pathway that links stress to eczema flare-ups

A new study using mouse models and multi-omics analysis has traced a specific nerve pathway through which prenatal stress programs fetal skin cells for eczema-like inflammation after birth. The ...

Itchy eyes? Experts reveal the causes and what you can do about them

Dry eyes are also a common source of itch - the result of hormonal changes related to aging, taking certain medications, some autoimmune diseases like rheumatoid arthritis, and staring at screens ...
Nature

Stress can cause eczema to flare-up – now we know why

Scientists have identified the neurons that worsen the condition during stress. For people with eczema, stress can trigger ...
MedPage Today

FDA OKs First Drug for Liver Disease-Related Pruritus

The FDA approved linerixibat (Lynavoy) as the first drug indicated for cholestatic pruritus stemming from primary biliary cholangitis (PBC), drugmaker GSK announced on Thursday.
Medscape

Linerixibat (Lynavoy) for Cholestatic Pruritus Wins FDA Nod

The oral ileal bile acid transporter inhibitor significantly and rapidly reduced cholestatic pruritus in patients with PBC in the phase 3 GLISTEN trial.
The American Journal of Managed Care

FDA Approves Linerixibat for Cholestatic Pruritus in Primary Biliary Cholangitis

Linerixibat targets pruritus pathobiology in PBC by blocking ileal bile acid reuptake, aiming to lower circulating pruritogenic bile acid–related mediators. GLISTEN demonstrated greater 24-week WI-NRS ...
Fierce Pharma

After Alfasigma's GSK licensing deal, Lynavoy picks up FDA nod in rare liver disease

Alfasigma’s buzzer-beater bet on GSK’s rare liver disease prospect has paid off. | Lynavoy is now the first FDA-approved product that can treat cholestatic pruritus in patients with primary biliary ...
Share Prices

GSK hails US FDA approval of Lynavoy for cholestatic pruritis form

GSK PLC on Thursday said the US Food & Drug Administration approved Lynavoy for the treatment of cholestatic pruritus in patients with primary biliary cholangitis. The London-based pharmaceutical ...